- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05800210
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Priya Gurjar
- Phone Number: 352-273-6772
- Email: PMO@cancer.ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Recruiting
- University of Florida
-
Contact:
- Beate Greer
- Phone Number: 352-294-8744
- Email: bgreer01@ufl.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
A. Children, Adolescents, Young adults (ages 6 months to ≤39 years) with the following diseases may be eligible:
i. ALL
- ALL high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (≤15% blasts at time of registration), mixed phenotype acute leukemia (MPAL), persistent MRD (≥0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (≤44 chromosomes)) in first remission
- ALL in second remission and beyond
ii. AML
- History of AML induction/reinduction Failure (≤15% blasts at time of registration)
- AML in CR1 with poor cytogenetics (i.e., 12p, 5a, -7, FLT3 mutation/duplication, t(9;11) and others)
- AML with persistent minimal residual disease (MRD) in CR1(≥0.01% on flow or persistent abnormal karyotype detected by cytogenetics)
- AML CR2 or beyond
- AML in refractory relapse but ≤15% bone marrow leukemia blasts
- Therapy-related AML
iii. Juvenile MyeloMonocytic Leukemia (JMML)
- JMML in CR1 without CBL mutation
- JMML with recurrence of disease with or without CBL mutation
- JMML CR2 or beyond
iv. Chronic Myeloid Leukemia (CML)
1. CML in CR with regard to blast crisis
v. High Risk Myelodysplastic syndrome (MDS)
vi. Lymphoma: Hodgkin (HL) or Non-Hodgkin (NHL)
- HL or NHL with a history of induction failure
- HL or NHL in PR1 or PR2
- HL or NHL in CR2 or subsequent remission
B. Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen [as determined by the treating physician and approved by the PI] may be included).
C. HLA-matched (5-6/6) sibling donor, matched (8-10/10) unrelated donor available for stem cell donation, haplo-identical related donor (at least one full haplotype must be matched).
D. Karnofsky or Lansky score ≥60% at the time of enrollment. Karnofsky scores must be used for patients >16 years of age and Lansky scores for patients ≤16 years of age.
E. Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as:
i. Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 60% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen.
ii. Renal: Creatinine clearance or radioisotope GFR ≥60 mL/min/1.73 m2 or a serum creatinine based on age/gender
iii. Cardiac: Shortening fraction of ≥ 27% by echocardiogram) or ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA).
iv. Hepatic: SGOT (AST) or SGPT (ALT) < 5 x upper limit of normal (ULN) for age. Conjugated bilirubin < 2.5 mg/dL, unless attributable to Gilbert's Syndrome.
F. Written informed consent obtained from the subject or guardian and the subject agrees to comply with all the study-related procedures.
G. Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 8 weeks after the last dose of study drug to minimize the risk of pregnancy.
H. Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 8 weeks following the last dose of study drug.
Exclusion Criteria:
A. Patients with documented uncontrolled infection
B. Patients who have received allogeneic hematopoietic stem cell transplantation within 6 months, unless being done as a boost.
C. Patients with active ≥Grade 2 aGVHD.
D. Demonstrated lack of compliance with medical care.
E. Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after the last dose of study drug.
F. Females who are known to be pregnant or breastfeeding.
G. History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
H. Prisoners or subjects who are incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Allogeneic stem cell transplant with ⍺/β CD3+ T-cell and CD19+ B-cell depleted graft
|
Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute graft versus host disease (aGVHD) incidence
Time Frame: 100 days
|
Compare the incidence of grade II to IV aGVHD following allogeneic stem cell trasplantation utilizing α/β CD3+ T-cell and CD19+ B-cell depletion compared to historical controls by day +100
|
100 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-free survival
Time Frame: 2 years
|
Evaluate the event-free survival, which is defined as being alive and without evidence of disease relapse
|
2 years
|
Overall survival
Time Frame: 2 years
|
Evaluate the overall survival
|
2 years
|
Probability of hematopoietic engraftment
Time Frame: 100 days
|
Determine the probability of hematopoietic engraftment, as measured by the presence of donor chimerism >95% by day 100
|
100 days
|
Cytomegalovirus (CMV) viremia incidence
Time Frame: 1 year
|
Determine the incidence of CMV viremia.
Viremia is defined as >1000copies/mL present on at least 2 weekly tests or requiring therapy.
|
1 year
|
Epstein-Barr virus (EBV) viremia incidence
Time Frame: 1 year
|
Determine the incidence of EBV viremia.
Viremia is defined as >1000copies/mL present on at least 2 weekly tests or requiring therapy.
|
1 year
|
Adenovirus viremia incidence
Time Frame: 1 year
|
Determine the incidence of adenovirus viremia.
Viremia is defined as >1000copies/mL present on at least 2 weekly tests or requiring therapy.
|
1 year
|
Post-transplant lymphoproliferative disorder (PTLD) incidence
Time Frame: 1 year
|
Determine the incidence of PTLD
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jordan Milner, MD, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Myelodysplastic-Myeloproliferative Diseases
- Leukemia, Lymphoid
- Chronic Disease
- Lymphoma
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myeloid
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Leukemia, Myelomonocytic, Juvenile
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Other Study ID Numbers
- UF-PED-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Clinical Trials on Miltenyi CliniMACS Prodigy ® system
-
University of Colorado, DenverRecruitingHematologic DisordersUnited States
-
Miltenyi Biomedicine GmbHCity of Hope Comprehensive Cancer CenterNot yet recruitingHematological Malignancies
-
University of ChicagoRecruitingSickle Cell DiseaseUnited States
-
Porteus, Matthew, MDCalifornia Institute for Regenerative Medicine (CIRM)RecruitingHematologic DiseasesUnited States
-
Medical College of WisconsinRecruitingLeukemia | Burkitt Lymphoma | Lymphoblastic Lymphoma | Myelodysplasia | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Chronic Myelogenous Leukemia - Chronic Phase | Chronic Myelogenous Leukemia, Accelerated Phase | Biphenotypic Acute Leukemia | Burkitt Leukemia | Chronic... and other conditionsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedLeukemia, Myeloid, Acute | Leukemia, Lymphoblastic, Acute | Leukemia, Myelocytic, ChronicUnited States
-
Children's Mercy Hospital Kansas CityUniversity of KansasCompletedNeuroblastomaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingMyelodysplastic Syndrome (MDS) | Severe Aplastic Anemia | Hypo-Plastic MDSUnited States
-
M.D. Anderson Cancer CenterRecruitingBlood And Marrow TransplantationUnited States
-
Neena Kapoor, M.D.Not yet recruitingAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Hematologic Malignancy | Graft Vs Host Disease | Graft-versus-host-disease | Non-hematologic Malignancy